@article { author = {Chauhan, Aman and Farooqui, Zainab and Silva, Scott R and Murray, Le Aundra and Hodges, Kurt B and Yu, Qian and Myint, Zin W and Raajesekar, Arumugam K and Weiss, Heidi and Arnold, Susanne and Evers, B Mark and Anthony, Lowell}, title = {Integrating a 92-Gene Expression Analysis for the Management of Neuroendocrine Tumors of Unknown Primary}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {20}, number = {1}, pages = {113-116}, year = {2019}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {10.31557/APJCP.2019.20.1.113}, abstract = {Background: Neuroendocrine tumors (NETs) are rare tumors that can originate from any part of the body. Often,imaging or exploratory surgery can assist in the identification of the tumor primary site, which is critical to themanagement of the disease. Neuroendocrine tumors (NETs) of unknown primary constitute approximately 10-15%of all NETs. Determining the original site of the tumor is critical to providing appropriate and effective treatment.Methods: We performed a retrospective review of neuroendocrine tumors at our institution between 2012 and 2016using a 92-gene cancer ID analysis. Results: 56 patients with NETs of unknown primary were identified. Samplesfor 38 of the 56 underwent the 92-gene cancer ID analysis. The primary site of the tumor was identified with >95%certainty in 35 of the 38 patients. Conclusion: The 92-gene cancer ID analysis identified a primary site in 92% of ourNETs study cohort that previously had been unknown. The results have direct implications on management of patientswith regard to FDA-approved treatment options.}, keywords = {Neuroendocrine tumor,tumor of unknown primary,92-gene cancer ID assay}, url = {https://journal.waocp.org/article_81959.html}, eprint = {https://journal.waocp.org/article_81959_27aa51ddd6f3b548f03a0321474b1704.pdf} }